Long-term safety and efficacy of guanfacine extended release in children and adolescents with ADHD
Tóm tắt
Data are reported from SPD503-318, a phase 3, open-label, safety study of guanfacine extended release (GXR) in European children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Participants received dose-optimized GXR (1–7 mg/day) for up to 2 years. Of 215 enrolled participants, 214 were included in the safety population and 133 completed the study. Participants’ mean age was 11.7 years and 73.8% were male. Overall, 177 participants (82.7%) experienced a treatment-emergent adverse event (TEAE). TEAEs reported in at least 10% of participants were somnolence (36.0%), headache (28.5%), fatigue (20.1%), and nasopharyngitis (11.7%). Serious TEAEs were reported in 4.7% of participants and TEAEs leading to discontinuation were reported in 3.3% of participants. There were no deaths. Mean z-scores for BMI were stable throughout the study. The incidence of sedative TEAEs (somnolence, sedation, and hypersomnia) peaked during week 3 and decreased thereafter. Small changes from baseline to the final assessment in mean supine pulse [− 5.5 bpm (standard deviation, 12.98)] and blood pressure [systolic, 0.6 mmHg (9.32); diastolic, 0.2 mmHg (9.17)] were reported. ADHD symptoms initially decreased and remained significantly lower than baseline at study endpoint. At the final assessment, the mean change in ADHD-RS-IV total score from baseline was − 19.8 (standard error of mean, 0.84; nominal p < 0.0001). In conclusion, GXR was well tolerated and more than 60% of participants completed the 2-year study.
Tài liệu tham khảo
Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA (2007) The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 164(6):942–948. https://doi.org/10.1176/ajp.2007.164.6.942
Polanczyk GV, Salum GA, Sugaya LS, Caye A, Rohde LA (2015) Annual research review: a meta-analysis of the worldwide prevalence of mental disorders in children and adolescents. J Child Psychol Psychiatry 56(3):345–365. https://doi.org/10.1111/jcpp.12381
Barkley RA, Fischer M, Smallish L, Fletcher K (2002) The persistence of attention-deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder. J Abnorm Psychol 111(2):279–289. https://doi.org/10.1037/0021-843X.111.2.279
Faraone SV, Biederman J, Mick E (2006) The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med 36(2):159–165. https://doi.org/10.1017/S003329170500471X
Arnold LE, Hodgkins P, Caci H, Kahle J, Young S (2015) Effect of treatment modality on long-term outcomes in attention-deficit/hyperactivity disorder: a systematic review. PLoS One 10(2):e0116407. https://doi.org/10.1371/journal.pone.0116407
The British Psychological Society and The Royal College of Psychiatrists (2016) The NICE guideline on diagnosis and management of ADHD in children, young people and adults. National Institute for Health and Care Excellence, London
Wolraich M, Brown L, Brown RT, DuPaul G, Earls M, Feldman HM, Ganiats TG, Kaplanek B, Meyer B, Perrin J, Pierce K, Reiff M, Stein MT, Visser S, Subcommittee on attention-deficit/hyperactivity disorder, steering committee on quality improvement and management (2011) ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 128(5):1007–1022. https://doi.org/10.1542/peds.2011-2654
Beau-Lejdstrom R, Douglas I, Evans SJ, Smeeth L (2016) Latest trends in ADHD drug prescribing patterns in children in the UK: prevalence, incidence and persistence. BMJ Open 6(6):e010508. https://doi.org/10.1136/bmjopen-2015-010508
Lachaine J, Beauchemin C, Sasane R, Hodgkins PS (2012) Treatment patterns, adherence, and persistence in ADHD: a Canadian perspective. Postgrad Med 124(3):139–148. https://doi.org/10.3810/pgm.2012.05.2557
Charach A, Figueroa M, Chen S, Ickowicz A, Schachar R (2006) Stimulant treatment over 5 years: effects on growth. J Am Acad Child Adolesc Psychiatry 45(4):415–421. https://doi.org/10.1097/01.chi.0000199026.91699.20
Swanson JM, Elliott GR, Greenhill LL, Wigal T, Arnold LE, Vitiello B, Hechtman L, Epstein JN, Pelham WE, Abikoff HB, Newcorn JH, Molina BS, Hinshaw SP, Wells KC, Hoza B, Jensen PS, Gibbons RD, Hur K, Stehli A, Davies M, March JS, Conners CK, Caron M, Volkow ND (2007) Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry 46(8):1015–1027. https://doi.org/10.1097/chi.0b013e3180686d7e
European Medicines Agency. Intuniv: EPAR—product information (2015). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003759/WC500195130.pdf. Accessed 21 December 2016
Vannucci A, Nelson EE, Bongiorno DM, Pine DS, Yanovski JA, Tanofsky-Kraff M (2015) Behavioral and neurodevelopmental precursors to binge-type eating disorders: support for the role of negative valence systems. Psychol Med 45(14):2921–2936. https://doi.org/10.1017/s003329171500104x
Intuniv® (guanfacine) capsules US prescribing information (revised March 2016). http://pi.shirecontent.com/PI/PDFs/Intuniv_USA_ENG.pdf. Accessed 14 October 2016
Biederman J, Melmed RD, Patel A, McBurnett K, Konow J, Lyne A, Scherer N (2008) A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 121(1):e73–e84. https://doi.org/10.1542/peds.2006-3695
Sallee FR, McGough J, Wigal T, Donahue J, Lyne A, Biederman J, SPD503 Study Group (2009) Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 48(2):155–165. https://doi.org/10.1097/chi.0b013e318191769e
Hervas A, Huss M, Johnson M, McNicholas F, van Stralen J, Sreckovic S, Lyne A, Bloomfield R, Sikirica V, Robertson B (2014) Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial. Eur Neuropsychopharmacol 24(12):1861–1872. https://doi.org/10.1016/j.euroneuro.2014.09.014
Wilens TE, Robertson B, Sikirica V, Harper L, Young JL, Bloomfield R, Lyne A, Rynkowski G, Cutler AJ (2015) A randomized, placebo-controlled trial of guanfacine extended release in adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 54(11):916–925. https://doi.org/10.1016/j.jaac.2015.08.016 (e912)
Newcorn JH, Harpin V, Huss M, Lyne A, Sikirica V, Johnson M, Ramos-Quiroga JA, van Stralen J, Dutray B, Sreckovic S, Bloomfield R, Robertson B (2016) Extended-release guanfacine hydrochloride in 6–17-year olds with ADHD: a randomised-withdrawal maintenance of efficacy study. J Child Psychol Psychiatry 57(6):717–728. https://doi.org/10.1111/jcpp.12492
Biederman J, Melmed RD, Patel A, McBurnett K, Donahue J, Lyne A (2008) Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD. CNS Spectr 13(12):1047–1055. https://doi.org/10.1017/S1092852900017107
Sallee FR, Lyne A, Wigal T, McGough JJ (2009) Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 19(3):215–226. https://doi.org/10.1089/cap.2008.0080
European Medicines Agency. Summary of the risk management plan (RMP) for Intuniv (guanfacine) (2015). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Risk-management-plan_summary/human/003759/WC500190181.pdf. Accessed 21 December 2016
Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, Mei Z, Wei R, Curtin LR, Roche AF, Johnson CL (2002) 2000 CDC Growth Charts for the United States: methods and development. Vital Health Stat 11(246):1–190
DuPaul GJ (1998) ADHD Rating Scale-IV: checklists, norms, and clinical interpretation. Guilford Press, New York
Guy W (1976) Clinical global impressions. The ECDEU assessment manual for psychopharmacology-revised volume, 338th edn. US Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs, Rockville, pp 218–222